Fundraising FoxF-Prime Capital
also invests · investor profileBoston, US · 9 known investors
Find your way into F-Prime Capital
Beam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.
Founders & leadership
Investors · 9
How we know: the company's own site · funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMay 2026
F-Prime Capital (lead)
Source ↗ - Undisclosed amountSeries BSep 2021
F-Prime Capital (lead)
Source ↗ - Undisclosed amountSeries BJan 2018
F-Prime Capital Partners (lead), Kaiser Permanente Ventures (lead), Arthur Ventures, Cognosante Ventures, Lionbird Venture Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does F-Prime Capital do?
- Beam Therapeutics develops CRISPR base editing technology to create precision genetic medicines for treating human diseases. The company focuses on therapeutic applications using single-letter DNA modifications.
- Who are F-Prime Capital's investors?
- F-Prime Capital's investors include F-Prime Capital, ASTUTIA Ventures GmbH, Golden Sparrow Ventures, Llc, Arthur Ventures, Brevan Howard Digital, Kaiser Permanente Ventures, White Star Capital.
- Where is F-Prime Capital headquartered?
- F-Prime Capital is headquartered in Boston, US.